An Experimental Study That Investigates Effects of Atreleuton in Metabolic Syndrome

Özet

The inflammation, LDL oxidation, and insulin resistance play an important role in the development of metabolic syndrome (MetS). This study aims to investigate the effects of atreleuton on serum lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), leukotriene B4 (LTB-4), insulin, and adipose tissue glucose transporter 4 (GLUT-4) levels in an experimental MetS model in rats. The rats were randomly divided into 3 groups: Group 1 (control, n = 7); Group 2 (MetS group, n = 8), Group 3 (MetS+atreleuton administered group, atreleuton(25 mg/kg/day) was administrated orally by gavage during the last 4 weeks of the experiment). MetS was created by feeding rats with high fructose andfat diet for 10 weeks in groups 2 and 3. Measurements of test parameters were made by ELISA method. The atreleuton caused a significant decrease in levels of serum LTB-4, LOX-1, insulin, and homeostatic model assessment for insulin resistance (HOMA-IR), while significantly increase on quantitative insulin sensitivity check index (QUICKI). However, atreleuton did not cause a significant change in tissue GLUT-4 level. The results of this study suggest that atreleutonmay be a protective agent against MetS complications by decreasing the levels of LTB-4 and LOX-1 that play an important role in MetS pathogenesis. Besides, the effect of atreleuton on the tissue GLUT-4 pathway needs to be supported by further studies.